Skip to main content
LG CHEM LTD logo

LG CHEM LTD — Investor Relations & Filings

Ticker · 051910 ISIN · KR7051910008 LEI · 988400IES4EIG7O06940 KO Manufacturing
Open in API
Filings indexed 711 across all filing types
Latest filing 2025-04-01 Major Shareholding Noti…
Country KR South Korea
Listing KO 051910

About LG CHEM LTD

https://www.lgchem.com/main/index?lang=…

LG Chem is a global science company with a diversified business portfolio in three core areas: Petrochemicals, Advanced Materials, and Life Sciences. The Petrochemicals division operates a vertically integrated system producing basic raw materials and downstream products like PE, ABS, and synthetic rubber. The Advanced Materials division focuses on specialty materials, with a strategic emphasis on becoming a comprehensive global supplier of battery materials. The Life Sciences division is focused on developing innovative new drugs for the global pharmaceutical market. The company prioritizes sustainability and R&D, aiming to develop eco-friendly materials and achieve carbon-neutral growth.

Recent filings

Filing Released Lang Actions
주식등의대량보유상황보고서(약식)
Major Shareholding Notification Classification · 100% confidence The document is a 'Report on the Status of Large Shareholdings' (주식등의 대량보유상황보고서) filed by the National Pension Service regarding LG Chem. This is a standard regulatory filing in South Korea (often referred to as a 5% report) used to notify the market of significant changes in share ownership. Based on the provided categories, this fits the 'Major Shareholding Notification' (MRQ) classification.
2025-04-01 Korean
유형자산처분결정(종속회사의주요경영사항)
Major Shareholding Notification Classification · 100% confidence The document is a regulatory disclosure regarding the disposal of tangible assets (property and buildings) by a subsidiary (Ultium Cells LLC) of LG Chem. It details the transaction amount, the counterparty, the purpose of the disposal, and the board resolution date. This type of corporate event disclosure, which does not fit into specific categories like M&A or share issues, is classified as a general regulatory filing.
2025-04-01 Korean
유형자산취득결정(종속회사의주요경영사항)
Regulatory Filings Classification · 100% confidence The document is a regulatory filing from LG Chem regarding a 'Decision to Acquire Tangible Assets' (유형자산 취득결정) by its subsidiary, LG Energy Solution Michigan, Inc. It details the acquisition of assets related to the Ultium Cells plant, including the transaction amount, purpose, and board approval date. Since this is a specific corporate disclosure regarding a significant business transaction (asset acquisition) that does not fit into categories like M&A (which usually refers to company takeovers) or share-related filings, it falls under the general regulatory filing category.
2025-04-01 Korean
[기재정정]유상증자결정(종속회사의주요경영사항)
Share Issue/Capital Change Classification · 100% confidence The document is a regulatory filing from LG Chem regarding a 'Correction Report' (정정신고) for a previous 'Decision on Capital Increase' (유상증자결정) concerning its subsidiary, LG Energy Solution Michigan, Inc. It details changes to the purpose of funds, the termination of a joint venture capital increase, and the acquisition of assets. This falls under capital structure and financing updates, specifically categorized as a Capital/Financing Update (CAP).
2025-04-01 Korean
[기재정정]유상증자결정(종속회사의주요경영사항)
Share Issue/Capital Change Classification · 100% confidence The document is a regulatory filing from LG Chem regarding a 'Correction Report' (정정신고) for a previously announced capital increase (유상증자결정) of a subsidiary, Ultium Cells LLC. It details changes to the funding purpose, payment dates, and the early termination of the capital increase due to a change in business strategy (asset acquisition). As this is a formal regulatory announcement regarding capital structure and financing activities, it falls under the 'Capital/Financing Update' category.
2025-04-01 Korean
투자판단관련주요경영사항
Legal Proceedings Report Classification · 100% confidence The document is a regulatory filing from LG Chem regarding the voluntary discontinuation of a Phase 3 clinical trial (EURELIA-2 study) for a gout treatment. This type of disclosure, which reports a significant operational or strategic change affecting the company's business activities, is classified as a regulatory announcement. Since it does not fit into specific categories like M&A, dividends, or financial reports, it falls under the general regulatory filing category.
2025-03-27 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.